The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
The design of semi-synthetic and synthetic glycoconjugate vaccines
Abstract
INTRODUCTION: Glycoconjugate vaccines are among the safest and most efficacious vaccines developed during the last 30 years. They are a potent tool for prevention of life-threatening bacterial infectious diseases like meningitis and pneumonia. The concept of hapten-carrier conjugation is now being extended to other disease areas. AREAS COVERED: This is an overview of the history and current status of glycoconjugate vaccines. The authors discuss the approaches for their preparation and quality control as well as those variables which might affect their product profile. The authors also look at the potential to develop fully synthetic conjugate vaccines based on the progress of organic chemistry. Additionally, new applications of conjugate vaccines technology in the field of non-infectious diseases are discussed. Through this review, the reader will have an insight regarding the issues and complexities involved in the preparation and characterization of conjugate vaccines, the variables that might affect their immunogenicity and the potential for future applications. EXPERT OPINION: The immunogenicity of weak T-independent antigens can be increased in quantity and quality by conjugation to protein carriers, which provide T-cell help. Glycoconjugate vaccines are among the safest and most efficacious vaccines developed so far. Various conjugation procedures and carrier proteins can be used. Many variables impact on the immunogenicity of conjugate vaccines and a tight control through physicochemical tests is important to ensure manufacturing and clinical consistency. New and challenging targets for conjugate vaccines are represented by cancer and other non-infectious diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Decline of Childhood Haemophilus influenzae Type b (Hib) Disease in the Hib Vaccine Era
Adams, W. G. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500020055031 · Cited by 696
Can Alzheimer disease be prevented by amyloid-β immunotherapy?
Lemere, C. A., & Masliah, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.219 · Cited by 351
Robust immune responses elicited by a fully synthetic three-component vaccine
Ingale, S., Wolfert, M. A., Gaekwad, J., Buskas, T., & Boons, G.-J. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.25 · Cited by 337
Kelly, D. F., Pollard, A. J., & Moxon, E. R. (2005) · JAMA · doi:10.1001/jama.294.23.3019 · Cited by 113
Pöllabauer, E. M., Petermann, R., & Ehrlich, H. J. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.005 · Cited by 58
Cited by
Adaptive immune activation: glycosylation does matter
Wolfert, M. A., & Boons, G.-J. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1403 · Cited by 327
Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C.-H. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 257
Metadata
- Authors
- Costantino, P., Rappuoli, R., & Berti, F.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2011-09-06
- Volume
- 6
- Issue
- 10
- Pages
- 1045-1066
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2050057463
- Cited by
- 210
- References
- 5
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The design of semi-synthetic and synthetic glycoconjugate vaccines. https://app.cochat.ai/papers/10.1517/17460441.2011.609554
- The paper
- Costantino, P., Rappuoli, R., & Berti, F. (2011). The design of semi-synthetic and synthetic glycoconjugate vaccines. Expert Opinion on Drug Discovery. https://doi.org/10.1517/17460441.2011.609554
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.